Amgen, Abgenix win fast-track for experimental cancer therapy

The FDA has given its fast track designation to Amgen and Abgenix for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor, for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment. News that the cancer drug was being put on a swift review process sent shares of both companies higher this morning.

- read this press release for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.